



## COMPANY FACTS

Founded 2007  
 Stock Exchange NASDAQ Stockholm (HNSA)  
 Headquarters Lund, Sweden  
 Operations Europe and the U.S.  
 Employees 162

**Key Executives**  
 Peter Nicklin Chairman  
 Søren Tulstrup President & CEO  
 Donato Spota SVP & CFO  
 Matthew Shaulis CCO & U.S. President  
 Achim Kaufhold SVP & CMO, interim CSO

## MARKET DATA (Q2 2023)

Market Cap USD ~228m  
 52 Week Range SEK 42-98  
 Avg. Daily Turnover vol. 277k shares  
 Shares Outstanding 52m

## Top 5 Shareholders

Redmile Group 20.3%  
 Avanza Pension 4.5%  
 Fjärde AP-fonden (AP4) 4.2%  
 Nexttobe AB 4.1%  
 Thomas Olsson 3.7%

## SHARE PRICE CHART (12M)



## KEY FINANCIALS

| SEKm                    | 2020  | 2021 | 2022  | H1'23 |
|-------------------------|-------|------|-------|-------|
| Revenue                 | 6     | 34   | 155   | 61    |
| R&D cost                | -227  | -231 | -346  | -208  |
| Net loss                | -421  | -548 | -610  | -251  |
| Cash & Short investment | 1,378 | 889  | 1,496 | 1,103 |
| Operating Cash Flow     | -290  | -481 | -504  | -389  |
| Employees               | 87    | 133  | 150   | 162   |

\* Unaudited

## CALENDAR

|               |                                                        |
|---------------|--------------------------------------------------------|
| July 20, 2023 | Half-year Report for January-June 2023                 |
| Aug 23, 2023  | Carnegie non-deal road show, Stockholm                 |
| Aug 24, 2023  | Erik Penser Company Day, Stockholm                     |
| Aug 31, 2023  | HC Andersen – Life Science seminar (virtual)           |
| Sep 11, 2023  | HC Wainwright Global Investment Conference, NYC        |
| Sep 11, 2023  | MorganS Global Healthcare Conference, NYC              |
| Sep 14, 2023  | Pareto Annual Healthcare Conference, Stockholm         |
| Sep 14, 2023  | Erik Penser Company Day, Malmö                         |
| Oct 2, 2023   | Redeye: Autoimmune and inflammatory disease, Stockholm |
| Oct 5-6, 2023 | Cowen US non-deal road show                            |
| Oct 12, 2023  | Redeye: Afterwork, Malmö                               |
| Oct 19, 2023  | Interim Report for January-September 2023              |
| Nov 21, 2023  | SEB Healthcare Seminar 2023, Stockholm                 |
| Nov 22, 2023  | Ökonomisk Ugebev Life Science event, Copenhagen        |

## CONTACTS

Klaus Sindahl  
 Head of Investor Relations  
 M: +46(0)709-298 269  
 klaus.sindahl@hansabiopharma.com

Stephanie Kenney  
 VP Global Corp. Affairs  
 M: +1 (484) 319 2802  
 stephanie.kenney@hansabiopharma.com

...at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

## ABOUT HANSA BIOPHARMA

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases and gene therapy. Hansa Biopharma is based in Lund, Sweden with operations in Europe and in the U.S.

## BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

| Candidate  | Indication                                                                                  | Clinical Development Phases |           |                                     |         |                         |          |
|------------|---------------------------------------------------------------------------------------------|-----------------------------|-----------|-------------------------------------|---------|-------------------------|----------|
|            |                                                                                             | Research/Preclinical        | Phase 1   | Potentially Pivotal program/Phase 2 | Phase 3 | Marketing Authorization | Marketed |
|            | EU: Kidney transplantation in highly sensitized patients <sup>1,2</sup>                     | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | US: Kidney transplantation in highly sensitized patients <sup>1,2</sup>                     | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Anti-GBM antibody disease <sup>3</sup>                                                      | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Antibody mediated kidney transplant rejection (AMR)                                         | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Guillain-Barré syndrome (GBS)                                                               | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
| Imlifidase | ANCA-associated vasculitis <sup>4</sup>                                                     | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (Partnered with Sarepta) | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)                 | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)                | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
|            | Pre-treatment ahead of gene therapy in Crigler-Najjar disease (Partnered with Genethon)     | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |
| HNSA-5487  | Lead molecule from second-generation IgG antibody cleaving enzymes (NiceR)                  | Completed                   | Completed | Completed                           | Ongoing | Planned                 | Planned  |

<sup>1</sup> Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)  
<sup>2</sup> Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al. New England Journal of Medicine)  
<sup>3</sup> Investigator-initiated study by Märten Segelmark, Professor at the universities in Linköping and Lund  
<sup>4</sup> Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard at Charité Universitätsmedizin Berlin

## STRATEGIC PRIORITIES



### Commercialize Idefix® in first indications and markets

- Successfully launch Idefix® in Europe
- Secure FDA approval and launch Idefix® in the U.S.
- Geographical expansion



### Advance ongoing imlifidase clinical programs in transplantation and autoimmune diseases

- Achieve approval/usage of imlifidase in follow-on indications
- Broaden our Idefix® label beyond kidney transplantation



### Expand IgG-cleaving enzyme technology platform into new disease areas and indications


- Explore gene therapy opportunity
- Explore opportunities in Oncology and stem cell transplantation (HSCT)
- Develop our next generation IgG-cleaving enzymes to allow for recurring treatment

## ACHIEVED AND UPCOMING MILESTONES

| 2023                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                        | 2024                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| H1 2023                                                                                                                                                                                                                                                                                                                                                                                                                                           | H2 2023                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                           |
| <ul style="list-style-type: none"> <li>U.S. ConfideS (Kidney tx) Phase 3: Complete enrollment</li> <li>Anti-GBM disease Phase 3: First patient enrolled</li> <li>GBS Phase 2: Complete enrollment</li> <li>ANCA-associated vasculitis Phase 2: First patient enrolled</li> <li>HNSA-5487 (Lead NiceR candidate): Initiate Phase 1 study</li> <li>Genethon Crigler-Najjar: Initiate preclinical study with imlifidase prior to GNT-0003</li> </ul> | <ul style="list-style-type: none"> <li>U.S. ConfideS (Kidney tx) Phase 3: Complete randomization</li> <li>GBS Phase 2: First data readout</li> <li>AMR Phase 2: Full data readout</li> <li>Long-term follow-up (Kidney tx): 5-year data readout</li> <li>Sarepta DMD pre-treatment Phase 1b: Commence clinical study</li> <li>HNSA-5487 (Lead NiceR candidate): Completion of Phase 1 study</li> </ul> | <ul style="list-style-type: none"> <li>U.S. ConfideS (Kidney tx) Phase 3: BLA submission</li> <li>GBS Phase 2: Outcome of the comparative efficacy analysis to IGOS data</li> <li>Genethon Crigler-Najjar Phase 1/2: Initiate clinical study with imlifidase prior to GNT-0003</li> </ul> |


## Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection




## Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')<sub>2</sub> fragment and one homo-dimeric Fc-fragment




## Imlifidase inactivates IgG in 2-6 hours


- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



## OUR BUSINESS MODEL



## Potential indication universe



\*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.

\*\*) In the US a new study has commenced targeting a BLA filing in 2024